PMV Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2013-01-01
- Employees
- 63
- Market Cap
- $81.4M
- Website
- http://www.pmvpharma.com
- Introduction
PMV Pharmaceuticals, Inc. is a precision oncology company, which engages in the discovery and development of small molecule, tumor-agnostic therapies targeting p53. The company was founded by Arnold J. Levine, David Henry Mac, and Thomas E. Shenk in March 2013 and is headquartered in Princeton, NJ.
A Study to Investigate the Effects of Itraconazole on the Pharmacokinetics of PC14586 in Healthy Participants
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- PMV Pharmaceuticals, Inc
- Target Recruit Count
- 12
- Registration Number
- NCT06362642
- Locations
- 🇺🇸
Fortrea, Madison, Wisconsin, United States
A Study to Investigate the Effects of Acid Reducing Agents on Pharmacokinetics of PC14586 in Healthy Participants
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2023-09-26
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- PMV Pharmaceuticals, Inc
- Target Recruit Count
- 28
- Registration Number
- NCT06054464
- Locations
- 🇺🇸
Parexel International, Baltimore, Maryland, United States
AME Study of [14C]-PC14586 in Healthy Male Participants
- Conditions
- Healthy Male Volunteers
- Interventions
- Drug: [14C]-PC14586
- First Posted Date
- 2022-08-31
- Last Posted Date
- 2022-12-20
- Lead Sponsor
- PMV Pharmaceuticals, Inc
- Target Recruit Count
- 8
- Registration Number
- NCT05523687
- Locations
- 🇺🇸
Labcorp Clinical Research Unit Inc., Madison, Wisconsin, United States
Effect of Food on PC14586 in Healthy Volunteers and the PK of PC14586 in Healthy Japanese Volunteers
- First Posted Date
- 2022-02-21
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- PMV Pharmaceuticals, Inc
- Target Recruit Count
- 34
- Registration Number
- NCT05249348
- Locations
- 🇺🇸
Parexel Early Phase Clinical Unit - Los Angeles, Glendale, California, United States
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Conditions
- Advanced Solid TumorAdvanced Malignant NeoplasmMetastatic CancerMetastatic Solid TumorLung CancerOvarian CancerEndometrial CancerProstate CancerColorectal CancerBreast Cancer
- Interventions
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- PMV Pharmaceuticals, Inc
- Target Recruit Count
- 230
- Registration Number
- NCT04585750
- Locations
- 🇰🇷
Seoul University Hospital, Seoul, Korea, Republic of
🇺🇸Hoag Cancer Center, Irvine, California, United States
🇺🇸University of California Irvine Chao Family Comprehensive Cancer Center, Irvine, California, United States